WebJul 21, 2024 · Two studies 25, 27 enrolled patients with statin intolerance receiving no statin, low‐dose statin, or maximally tolerated statin therapy. Fasting LDL‐C required at randomization was ≥100 mg/dL for Ballantyne et al, 27 whereas for Laufs et al, 25 it was ≥100 mg/dL for patients with atherosclerotic cardiovascular disease or ≥130 mg/dL for … WebHistorically, however, fibrate–statin combination therapy has been a source of safety concerns. In the NEPTUNE survey, 21 25% of patients receiving treatment for dyslipidaemia had triglyceride levels >200mg/dl. Only 27% of patients with hypertriglyceridaemia and CAD had achieved their non-HDL treatment goals.
Safety and Tolerability of PCSK9 Inhibitors: Current Insights
WebMar 4, 2024 · Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet. 2024;393:407-415. doi: 10.1016/S0140-6736(18)31942-1. 16. WebFurthermore, a very recent prespecified analysis of the BERSON clinical trial (a double-blind, randomized, placebo-controlled, multicenter study, which evaluated the safety and efficacy of evolocumab in combination with statin therapy in diabetic subjects with hyperlipidemia or mixed dyslipidemia) assessed the effect of 12 weeks of treatment ... buuctf musicblog
Safety and efficacy of statins - The Lancet
WebMar 18, 2024 · The 2016 Review by Rory Collins and colleagues (Nov 19, p 2532),1 of evidence about the efficacy and safety of statin therapy, claims that the 2012 Cholesterol … WebMar 25, 2024 · The addition of pemafibrate to statin therapy only led to a significant increase in serum concentrations of creatinine compared with placebo at a dose of 0.2 mg twice a day. ... Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: ... WebJul 18, 2024 · Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomized, open-label, non-inferiority trial. Lancet 2024;400:380-90. buuctf music